Corvus Pharmaceuticals, INC

Corvus Pharmaceuticals announces the resignation of director Ian T. Clark, effective July 22, 2026, after nine years of service.

Corvus Pharmaceuticals stockholders re-elected directors, ratified auditors, and approved executive compensation at the 2026 Annual Meeting.

Corvus Pharmaceuticals announced positive final data from a Phase 1 trial of soquelitinib for atopic dermatitis, showing safety, efficacy, and potential for durable, drug-free remissions.

Corvus Pharmaceuticals reported first quarter 2026 financial results, highlighting positive Phase 1 data for soquelitinib in atopic dermatitis and a strengthened cash position following a January financing.

Corvus Pharmaceuticals appoints Dr. Andrew C. Chan to its Board of Directors as Scott Morrison resigns.

Corvus Pharmaceuticals, Inc. amended its at-the-market sales agreement with Jefferies LLC, increasing the potential aggregate offering price for common stock sales to $200 million.

Corvus Pharmaceuticals reports reduced net loss in Q3 2025 driven by warrant revaluation, positive clinical data for soquelitinib, but faces substantial doubt about its ability to continue as a going concern.

Corvus Pharmaceuticals reported a net income for the first six months of 2025 driven by a warrant revaluation gain, while advancing its lead drug candidates soquelitinib and ciforadenant in clinical trials.

Corvus Pharmaceuticals reports a net income of $15.2 million for Q1 2025, primarily due to a significant decrease in warrant liability, while continuing to advance its clinical development programs.

Corvus Pharmaceuticals reported a net loss of $40.2 million for Q3 2024, while highlighting clinical advancements and a strengthened financial position through recent capital raises.

Corvus Pharmaceuticals reports a net loss of $10.0 million for the first six months of 2024, while advancing its clinical programs for soquelitinib, ciforadenant, and mupadolimab.

Corvus Pharmaceuticals reports a net loss of $5.7 million for the first quarter of 2024, while advancing its clinical programs and securing additional funding.

Corvus Pharmaceuticals reports a significant net loss for 2024 and expresses substantial doubt about its ability to continue as a going concern.

Corvus Pharmaceuticals details its 2023 financial results and provides updates on the clinical development of its lead drug candidates, including soquelitinib, ciforadenant, and mupadolimab.

Corvus Pharmaceuticals director David Scott Moore acquired 21,700 shares and received 15,000 stock options in a recent filing.

Corvus Pharmaceuticals director Ian T. Clark was granted 15,000 stock options as part of his compensation package.

Corvus Pharmaceuticals director Linda Grais was granted 15,000 stock options as part of standard equity compensation.

Corvus Pharmaceuticals director and 10% owner Peter A. Thompson was granted 15,000 stock options with an exercise price of $11.6.

Richard van den Broek, a Director at Corvus Pharmaceuticals, acquired 15,000 stock options on June 11, 2026, with an exercise price of $11.60.

Richard A. Miller, President and CEO of Corvus Pharmaceuticals, reported transactions involving the acquisition and disposition of company stock.

Corvus Pharmaceuticals has issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.

Corvus Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on director elections, auditor ratification, and executive compensation.

Corvus Pharmaceuticals will hold its annual meeting of stockholders virtually on June 12, 2025, to vote on director elections, ratification of the accounting firm, and executive compensation.

Corvus Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on June 13, 2024, to vote on director election, auditor ratification, and executive compensation.

Corvus Pharmaceuticals will hold its annual stockholders meeting virtually on June 13, 2024, to vote on director election, auditor ratification, and executive compensation.

Adams Street Partners, LLC updated its beneficial ownership in Corvus Pharmaceuticals, Inc. to 3.9% following a recent public offering by the issuer.

OrbiMed Advisors' beneficial ownership in Corvus Pharmaceuticals decreased to 10.3% following Corvus's recent public offering of 7.9 million shares.

OrbiMed Advisors LLC and OrbiMed Capital GP V LLC have filed an Amendment No. 11 to their Schedule 13D, reporting a decrease in their beneficial ownership of Corvus Pharmaceuticals, Inc. common stock to 12.2% due to a change in the number of outstanding shares.

OrbiMed Advisors and OrbiMed Capital GP V have filed an amendment to their Schedule 13D, disclosing an increased beneficial ownership of 13.8% in Corvus Pharmaceuticals, Inc. and an expanded warrant exercise limitation.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in Corvus Pharmaceuticals, Inc. as of March 31, 2026.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 7.5% of Corvus Pharmaceuticals, Inc. common stock issuable upon warrant exercise.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in Corvus Pharmaceuticals Inc. due to an internal realignment.

Richard A. Miller and related entities disclose beneficial ownership of 7.8% of Corvus Pharmaceuticals, Inc. common stock.

The Vanguard Group has reported a 5.18% beneficial ownership stake in Corvus Pharmaceuticals Inc., held as a passive investment.

BlackRock, Inc. has reported a beneficial ownership of 5.4% of Corvus Pharmaceuticals Inc.'s common stock.